Preclinical trial data published online in the Journal of Molecular Medicine has revealed that administering non-psychotropic cannabis plant constituent cannabidiol (CBD) is protective in an experimental model of colon cancer.
The study, “Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer,” appeared in the Journal of Molecular Medicine.
Investigators at the University of Naples evaluated CBD effects on colon carcinogenesis in mice. It was reported by the researchers that administration of cannabidiol (CBD) as associated with cancerous tumor reduction and reduced cell proliferation.
Authors wrote: “Although cannabidiol has been shown to kill glioma cells, to inhibit cancer cell invasion and to reduce the growth of breast carcinoma and lung metastases in rodents, its effect on colon carcinogenesis has not been evaluated to date. This is an important omission, since colon cancer affects millions of individuals in Western countries.
In the present study, we have shown that cannabidiol exerts (1) protective effects in an experimental model of colon cancer and (2) antiproliferative actions in colorectal carcinoma cells.” It was also acknowledged by the authors that CBD possesses “an extremely safe profile in humans.” They concluded, “Our findings suggest that cannabidiol might be worthy of clinical consideration in colon cancer prevention.”
In December 2011, clinical review data published in the scientific journal Current Drug Safety concluded that cannabidiol is “non-toxic” to healthy cells and is “well tolerated” in humans.